This article is more than 5 years old. Information may no longer be current.
Santen microshunt study results lead news of the week
Click Here to Manage Email Alerts
Here are some of the past week’s top stories on Healio.com/OSN:
DE-128 microshunt reduced IOP, medications in study
A multicenter study found the DE-128 microshunt implanted intraoperatively with 0.2 mg/mL concentration of mitomycin C effectively reduced IOP in patients with primary open-angle glaucoma not controlled with maximum tolerated glaucoma medications. Read more.
Values over value: what the new workforce wants
One remarkable difference between younger aged workers and their baby boomer counterparts is that Generation Z and millennial workers will quit a job if their personal values do not align with that of the company they work for. Read more.
AmEx recalls all lots of bevacizumab
All lots of bevacizumab 1.25 mg/0.05 mL 31-gauge injectable and bevacizumab 2.5 mg/0.1 mL Normject TB injectable from Pacifico National, doing business as AmEx Pharmacy, have been voluntarily recalled by the company. Read more.
NHS England to fund Luxturna treatment
NHS England will fund Luxturna gene therapy treatment for inherited retinal dystrophies starting in January 2020. Read more.
OpRegen appears well tolerated in dry AMD
In patients with dry age-related macular degeneration, the implantation of human embryonic stem cell-derived retinal pigment epithelial cells was mostly well tolerated. Read more.